Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-03-15
2005-03-15
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S190100, C424S184100, C530S350000, C530S300000, C530S825000, C514S002600
Reexamination Certificate
active
06866855
ABSTRACT:
The GapC plasmin binding protein genes ofStreptococcus dysgalactiae(S. dysgalactiae),Streptococcus agalactiae(S. agalactiae),Streptococcus uberis(S. uberis),Streptococcus parauberis(S. parauberis), andStreptococcus iniae(S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.
REFERENCES:
patent: 4954618 (1990-09-01), Fahnestock
patent: 4977082 (1990-12-01), Boyle et al.
patent: 5108894 (1992-04-01), Bjorck et al.
patent: 5237050 (1993-08-01), Boyle et al.
patent: 5328996 (1994-07-01), Boyle et al.
patent: 5721339 (1998-02-01), Boyle et al.
patent: 5863543 (1999-01-01), Jiang et al.
patent: 20030072765 (2003-04-01), Potter et al.
patent: 0 887 410 (1998-12-01), None
patent: WO 9640928 (1996-12-01), None
patent: WO 9641879 (1996-12-01), None
patent: WO 9818930 (1998-05-01), None
patent: WO 9942588 (1999-08-01), None
patent: WO 0039299 (2000-07-01), None
patent: WO 0196381 (2001-12-01), None
Houghten et al. Vaccines86, Cold Spring Harbor Laboartory, pp. 21-25, 1986.*
Fontaine et al., “Immunization of Dairy Cattle With RecombinantStreptococcus uberisGapC or a Chimeric Camp Antigen Confers Protection Against Heterologous Bacterial Challenge,” Vaccine 20(17-18):2278-2286 (2002).
Leigh, Immunization of Dairy Cattle With RecombinantStreptococcus uberisGapC or a Chimeric Camp Antigen Confers Protection Against Heterologous Bacterial Challenge, M.C. Fontaine et al., Vaccine 20:2278-2286, Vaccine, Butterworth Scientific. Guilford, GB, 20:25-26 (2002).
Finch et al., “Further Studies on the Efficacy of a Live Vaccine Against Mastitis Caused byStreptococcusUberis,” Vaccine 15(10):1138-1143 (1997).
Gase et al., “Cloning Sequencing and Functional Overexpression of theStreptococcus equisimilisH46A gapC Gene Encoding a Glyceraldehyde-3-Phosphate Dehydrogenase that also Functions as a Plasmin(ogen)-Binding Protein. Purification and Biochemical Characterization of the Protein,”European Journal of Biochemistry 239(1):42-51 (1996).
Stollerman, G. H., “RheumatogenicStreptococcl and Autoimmunity,” Clin. Immunol. Immunopathology, 61:131-142 (1991).
Baird et al., “Epitopes of Group A Streptococcal M Protein Shared With Antigens of Articular Cartilage and Synovium,”The Journal of Immunology 146(9):3132-3137 (1991).
Bisno, Alan. L., “Group A Streptococcal Infections and Acute Rheumatic Fever,”New Eng J. Med. 325:783-793 (1991).
Bronze et al., “Epitopes of Streptococcal M Proteins that Evoke Antibodies That Cross-React with Human Brain,”The Journal of Immunology 151(5):2820-2828 (1993).
Cunningham et al., “Study of Heart-Reactive Antibody in Anlisera and Hybridoma Culture Fluids Against Group A Strepatococci,”Infection and Immunity 42(2):531-538 (1983).
Dale, J. L., “Multivalent Group A Streptococcal Vaccine Designed to Optimize the Immunogenicity of Six Tandem M Protein Fragments,”Vaccine 17(2):193-200 (1999).
Dale J. L. and Beachy, G. H., “Multiple, Heart-Cross Reactive Epitopes of Streptococcal M Proteins,”J. Exp. Med. 161:113-122 (1995).
Dale, J. L. and Beachy, G. H., “Protective Antigenic Determinant of Streptococcal M Protein Shared With Sarcolemmal Membrane Protein of Human Heart,”J. Exp. Med. 156:1165-1176 (1985).
Froude et al., “Cross-Reactivity BetweenStreptococcusand Human Tissue: A Model of Molecular Mimicry and Autoimmunity,”Microbiology and Immunology 145:5-26 (1989).
Kehoe, Michael A., “Group A Streptococcal Antigens and Vaccine Potential,”Vaccine 9:797-806 (1991).
Lancefield, Rebecca C., “Current Knowledge of Type-Specific M Antigens of Group A Streptococci,”J. of Immunology 89:307-313 (1962).
Langone, John J., “Protein A ofStaphylococcus aureusand Related Immunoglobulin Receptors Produced by Streptococci and Pneumonococci,”Advances in Immunology 32:167 (1982).
Llijeqvist et al., “Surface Display of Functional Fibronectin-Binding Domains onStaphylococcus camosus,” FEBS Letters 446:299-304 (1999).
Bolton Alexandra J.
Fontaine Michael
Perez-Casal Jose
Potter Andrew A.
Devi S.
Robins & Pasternak LLP
University of Saskatchewan
LandOfFree
Immunization of dairy cattle with GapC protein against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunization of dairy cattle with GapC protein against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunization of dairy cattle with GapC protein against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3419709